Asiantuntijamme ovat kirjoittaneet, osallistuneet ja antaneet näkemystä satoihin julkaisuihin.
Hallinen T, Soini E, et al. Cost-utility of tocilizumab in the treatment of systemic juvenile idiopathic arthritis in Finland. Annals of the Rheumatic Diseases 2013;71(Suppl3):258-9. Poster presented at the Annual European Congress of Rheumatology (EULAR) 2012, Berlin.
Manca A, Asseburg C, et al. The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS). Value Health 2012;15(1):22-31.
Hallinen T, Soini E, et al. Dabigatraanin kustannusvaikuttavuus eteisvärinäpotilaiden aivohalvausten ehkäisyssä. Dosis 2012;28:130-44.
Hallinen T, Soini E, et al. Cost-effectiveness of insulin glargine compared to other long-acting basal insulins in the treatment of Finnish type 1 and type 2 diabetes patients based on individual studies. Dosis 2012;28:145-64.
Peura PK, Martikainen JA, et al. Sponsorship-Related Outcome Selection Bias in Published Economic Studies of Triptans: Systematic Review. Med Decis Making 2012;32(2):237-45.
Cummins E, Asseburg C, et al. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ 2012;13(6):801-9.
Soini E, et al. Contingent Valuation of Eight New Treatments: What is the Clinician’s and Politician’s Willingness to Pay? The Open Complementary Medicine Journal 2012;4:1-11.
Soini E, Martikainen JA, et al. Economic evaluation of sequential treatments for follicular non-Hodgkin lymphoma. Clin Ther 2012;34(4):915-25.
Asseburg C, et al. Hospitalisation utilisation and costs in schizophrenia patients in Finland before and after switch to risperidone long-acting injection. Schizophr Res Treatment 2012; 2012: 791468.
Soini E, Hallinen TA, et al. Cost-effectiveness of adalimumab, etanercept and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ 2012;15(2):340-51.
Martikainen J, Asseburg C, et al. Triptaanien kustannusvaikuttavuus akuutin migreenikohtauksen hoidossa. Lääkealan turvallisuus- ja kehittämiskeskus Fimea. Fimea kehittää, arvioi ja informoi –julkaisusarja 1/2011.
GAO. Value in Health Care. Key Information for Policymakers to Assess Efforts to Improve Quality While Reducing Costs. Washington: United States Government Accountability Office’s Report to Congressional Requesters, 2011. One of the responders: Soini, E.
Soini E. Harvinaissairauksien taloudellinen arviointi: mitä päätöksien tueksi tulisi tuottaa? Harvinaiset Sairaudet -lehti 2011;1:26-31.
Peura P, Turunen J, Purmonen T, Happonen P, Martikainen J. Mitä lääkehoitojen kustannusvaikuttavuus tarkoittaa? Sic! 2/2011
Ramsberg J, Asseburg C, Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care -a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One 2012;7(8):e42003.
Hallinen T, Soini E, et al. Differential use of extended and immediate release quetiapine: A retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders. BMJ Open 2012;2(4):e000915.
Asseburg C, Peura P, Oksanen T, Turunen J, Purmonen T, Martikainen J. Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison. Int J Technol Assess Health Care 2012;28(4):382-9.
Willis M, Asseburg C, He J. Validation of Economic Simulation Models Using Clinical Trial Results: Experiences from Type 2 Diabetes Mellitus (T2DM). iHEA 2011. Podium. J Med Econ 2013;16(8):1007-21.
Willis M, Neslusan C, Asseburg C, et al. Initial HbA1c and HbA1c Lowering: Implications for Model-Based Economic Evaluations in Type 2 Diabetes Mellitus (T2DM). American Diabetes Association (ADA) meeting 2011. Podium.
Soini E, Martikainen J, et al. Cost-effectiveness of first-line rituximab maintenance treatment for follicular lymphoma. Haematologica 2011;96(s2):402. Poster at the Annual Congress of European Hematology Association (EHA 2011).
Soini E. Terveystaloustrendiksi todellisen hoitotilanteen kustannusvaikuttavuus. Impulssi 2011;3:16-7.
Soini E. Myytkö lisäkustannuksia vai kustannusvaikuttavuutta? Podium 2011;5:19.
Kokonaisuus ratkaisee kustannusvaikuttavuuden. BI News 2011;syksy. Suomen Lääkärilehden välissä julkaistu tiedotuslehtinen. Haastateltu: Soini, E.
Asseburg C, et al. Cost-Effectiveness of Targeted Therapy With Cetuximab in Patients With K-ras Wild-Type Colorectal Cancer Presenting With Initially Unresectable Metastases Limited to the Liver in a German Setting. Clin Ther 2011;33(4):482-97.
Soini E, et al. Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information. Ann Oncol 2011;22(1):215-23.
Soini E, Martikainen J, et al. Sequential treatment of follicular non-Hodgkin lymphoma: Cost-effectiveness and value of information. Value in Health 2011;14(7):A239-40. Podium at the Annual ISPOR European Congress.
Hallinen T, Soini E, et al. Differential use of extended and instant release quetiapine: A naturalistic study of Finnish inpatients with schizophrenia spectrum and bipolar disorders. Value in Health 2011;14(7):A299.
Theidel U, Asseburg C, et al. Cost effectiveness of ticagrelor in the treatment of acute coronary syndrome in Germany. Annual ISPOR European Congress 2011. Value in Health 2011;14(7):A376-7.
Martikainen J, Soini E, et al. The health economic consequences of reducing salt and replacing intake of saturated fat with polyunsaturated fat in the adult Finnish population – Estimates based on the FINRISK and FINDIET studies. Eur J Clin Nutr 2011;65()10:1148-55.
Soini E. Cost-utility and expected value of perfect information related to trabectedin in the treatment of metastatic soft-tissue sarcoma: the publicly funded comments explored. Ann Oncol 2011;22(6):1465-6.